MIRA INFORM REPORT
|
Report Date : |
21.10.2011 |
IDENTIFICATION DETAILS
|
Name : |
FRESENIUS
MEDICAL CARE ASIA-PACIFIC LTD. |
|
|
|
|
Registered Office : |
Room 5101-5123, 51/F., Sun Hung Kai Centre, 30 Harbour Road, Wanchai |
|
|
|
|
Country : |
Hong Kong |
|
|
|
|
Date of Incorporation : |
14.08.1998 |
|
|
|
|
Com. Reg. No.: |
21925598 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Importer, Exporter and Wholesaler of all kinds of medical disposable products, medical devices, etc. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment
Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made on
e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30th, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
Hong Kong |
a2 |
a2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name
FRESENIUS MEDICAL CARE ASIA-PACIFIC LTD.
Company ADDRESS
Room 5101-5123, 51/F., Sun Hung Kai Centre, 30 Harbour Road, Wanchai, Hong Kong.
PHONE: 2802 2900
FAX: 2598 9199
MANAGEMENT
Managing Director: Mr. Roberto Fuste Fernandez
SUMMARY
Incorporated on: 14th August, 1998.
Organization: Private Limited Company.
Capital: Nominal: HK$1,000.00
Issued: HK$2.00
Business Category: Importer, Exporter and Wholesaler.
Group Net Revenue: US$12,053,490,000 (Year ended 31-12-2010)
Employees: 30. (Including affiliates)
Group Employees: 73,452. (As at 31-12-2010)
Main Dealing Banker: The Hongkong & Shanghai Banking Corp. Ltd., Hong Kong.
Banking Relation: Satisfactory.
Company ADDRESS
Registered Head Office:-
Room 5101-5123, 51/F., Sun Hung Kai Centre, 30 Harbour Road, Wanchai, Hong Kong.
Holding Company:-
Fresenius Medical Care AG & Co. KGaA, Germany. [Formerly known as Fresenius Medical Care Beteiligungsgesellschaft mbH]
Associated Companies:-
FMC Group of Companies
· Asia Renal Care (South East Asia) Pte. Ltd., Singapore.
· BioCare Medical Co. Ltd., British Virgin Islands.
· Biocare Technology Co. Ltd., Hong Kong.
· Bioteque Corporation, Taiwan.
· Excelsior Renal Service Co. Ltd., Hong Kong.
· FMC (Schweiz) AG, Switzerland.
· FMC (Thailand) Ltd., Thailand.
· FMC (U.K.) Ltd., UK.
· FMC Argentina S.A., Argentina.
· FMC Australia Pty. Ltd., Australia.
· FMC Austria GmbH, Austria.
· FMC Belgium N.V., Belgium.
· FMC Ceska Republika spol. s.r.o., Czech Republic.
· FMC Colombia S.A., Colombia.
· FMC Danmark A/S, Denmark.
· FMC de Mexico S.A., Mexico.
· FMC de Peru S.A., Peru.
· FMC de Venezuela C.A., Venzuela.
· FMC Deutschland GmbH, Germany.
· FMC Dializis Center Eges. Kft., Hungary.
· FMC Espana S.A., Spain.
· FMC France S.A.S., France.
· FMC GmbH, Germany.
· FMC Holdings Inc., USA.
· FMC Hundry Ltd., Hungary.
· FMC India Pvt. Ltd., India.
· FMC Italia S.p.A., Italy.
· FMC Japan K.K., Japan.
· FMC Korea Ltd., South Korea.
· FMC Lebanon S.a.r.l., Lebanon.
· FMC Ltda., Brazil.
· FMC Malaysia Sdn. Bhd., Malaysia.
· FMC Maroc S.A., Marocco.
· FMC Nederland B.V., the Netherlands.
· FMC Nephrocare Polska Sp.z.o.o., Poland.
· FMC Pakistan (Private) Ltd., Pakistan.
· FMC Philippines Inc., Philippines.
· FMC Polska S.A., Poland.
· FMC Portugal S.A., Portugal.
· FMC Renalcare Corporation, Philippines.
· FMC Romania Srl, Romania.
· FMC Serige AB, Sweden.
· FMC Shanghai Co. Ltd., China.
· FMC Singapore Pte. Ltd., Singapore.
· FMC Slovenija d.o.o., Slovenia.
· FMC Slovensko spol s.r.o., Slovakia.
· FMC South Africa (Pty) Ltd., South Africa.
· FMC Srbija d.o.o., Serbia.
· FMC Suomi OY, Finland.
· FMC Taiwan Co. Ltd., Taiwan.
· Fresenius Institute of Dialysis Nursing Co. Ltd., Hong Kong.
· Fresenius Kabi Asia Pacific Ltd., Hong Kong.
· Fresenius Kabi Hong Kong Ltd., Hong Kong.
· Fresenius Medical Care (Jiangsu) Co. Ltd., China.
· Fresenius Medical Care Hong Kong Ltd., Hong Kong.
· Fresenius Medikal Hizmetler A.S., Turkey.
· Fresenius-Kawasumi Co. Ltd., Japan.
· Jiangsu Bioteque Biotechnology Co. Ltd., China.
· Jiate Excelsior Co. Ltd., India.
· Nefrodial d.o.o., Slovenia.
· NephroCare Korea Inc., South Korea.
· NMC Centro Mdico Nacional S.A., Portugal.
· NMC of Spain S.A., Spain.
· OU FMC Estonia, Estonia.
· P.T. FMC Indonesia, Indonesia.
· Pentafarma S.A., Chile.
· SIS-TER S.p.A., Italy.
· SMAD S.A., France.
· St. Paul Nephrocare Ltd., Hong Kong.
· ZAO Fresenius S.P., Russia.
etc.
BUSINESS REGISTRATION NUMBER
21925598
COMPANY FILE NUMBER
0652453
MANAGEMENT
Managing Director: Mr. Roberto Fuste Fernandez
CAPITAL
Nominal Share Capital: HK$1,000.00 (Divided into 1,000 shares of HK$1.00 each)
Issued Share Capital: HK$2.00
SHAREHOLDERS
(As per registry
dated 14-08-2011)
|
Name |
|
No. of shares |
|
Fresenius Medical Care AG & Co. KGaA Else-Kroner-Strasse 1, 61352 Bad Homburg v.d.H., Germany. |
|
1 |
|
Blue Tiger Ltd., Hong Kong. |
|
1 |
|
|
|
–– |
|
|
Total: |
2 == |
DIRECTORS
(As per registry
dated 14-08-2011)
|
Name (Nationality) |
Address |
|
Markus Andreas LOEFFLER |
Flat C, 15 Seahorse Lane, Discovery Bay, Lantau Island, Hong Kong. |
|
MA Yuk Ling, Betty |
Flat 1914, 19/F., Block A, Viking Villas, No. 70 Tin Hau Temple Road, Hong Kong. |
|
Thomas Georg MECHTERSHEIMER |
10 Kananook Avenue, Bayview, New South Wales, 2104, Australia. |
|
Frank Michael WAGNER |
House H, Caquecoy Villas 17 Ah Kung Wan Road, Clearwater Bay, Net Territories, Hong Kong. |
|
Roberto FUSTE FERNANDEZ |
Petanvia, House 8, Lot 10, DD231 Chuk Kok Village, Sai Kung, New Territories, Hong Kong. |
SECRETARY
(As per registry
dated 14-08-2011)
|
Name |
Address |
Co. No. |
|
Clarson Services Ltd. |
18/F., Edinburgh Tower, The Landmark, 15 Queen’s Road Central, Hong Kong. |
0582737 |
HISTORY
The subject was incorporated on 14th August, 1998 as a private limited liability company under the Hong Kong Companies Ordinance.
Originally the subject was registered under the name of Mitre House Bannana Ltd., name changed to the present style on 18 November, 1998.
Apart from these, neither material change nor amendment has been ever traced and noted.
OPERATIONS
Activities: Importer, Exporter and Wholesaler.
Lines: All kinds of medical disposable products, medical devices, etc.
Employees: 30. (Including affiliates)
Group Employees: 73,452. (As at 31-12-2010)
Materials/Commodities: Imports raw materials from European countries, some Asian countries and finished
products from China.
Markets: China, Europe, North America, etc.
Group Net Revenue: US$ 6,771,819,000 (Year ended 31-12-2005)
US$ 8,499,038,000 (Year ended 31-12-2006)
US$ 9,720,034,000 (Year ended 31-12-2007)
US$10,612,323,000 (Year ended 31-12-2008)
US$11,247,477,000 (Year ended 31-12-2009)
US$12,053,490,000 (Year ended 31-12-2010)
Terms/Sales: L/C or as per contracted.
Terms/Buying: L/C, T/T, etc.
FINANCIAL INFORMATION
Nominal Share Capital: HK$1,000.00 (Divided into 1,000 shares of HK$1.00 each)
Issued Share Capital: HK$2.00
Group Net Income: US$454,952,000 (Year ended 31-12-2005)
US$536,746,000 (Year ended 31-12-2006)
US$717,130,000 (Year ended 31-12-2007)
US$817,607,000 (Year ended 31-12-2008)
US$891,138,000 (Year ended 31-12-2009)
US$978,517,000 (Year ended 31-12-2010)
Profit or Loss: Group business is profitable.
Condition: Keeping in a active manner.
Facilities: Making active use of general banking facilities.
Payment: Met trade commitments as required.
Commercial Morality: Satisfactory.
Banker: The Hongkong & Shanghai Banking Corp. Ltd., Hong Kong.
Standing: Normal.
GENERAL
Fresenius
Medical Care Asia-Pacific Ltd. is equally owned by Fresenius Medical Care
AG & Co. KGaA [FMC], Germany, and Blue Tiger Ltd., Hong Kong. The subject has just issued 2 ordinary shares
of HK$1.00 each while each of the holding companies holds a single share.
The
subject is trading in the products of FMC.
FMC
is the world’s largest integrated provider of products and services for
individuals undergoing dialysis because of chronic kidney failure, a condition
that affects more than 1,890,000 individuals worldwide. Through its network of 2,599 dialysis clinics
in North America, Europe, Latin America, Asia-Pacific and Africa, FMC provides
dialysis treatment to 202,414 patients around the globe. FMC is also the world’s leading provider of
dialysis products such as hemodialysis machines, dialyzers and related
disposable products. FMC is listed on
the Frankfurt Stock Exchange and the New York Stock Exchange. FMC is the holding company of the FMC Group.
In
1996, FMC was founded. In 2006, it
acquired Renal Care Group Inc.
In 2007, FMC continued to be the leading manufacturer of dialyzers,
producing its 500 millionth dialyzer.
FMC is the world’s
largest integrated provider of products and services for individuals undergoing
dialysis because of chronic kidney failure, a condition that affects more than 2
million individuals worldwide. Through its network of 2,757 dialysis clinics in North America, Europe, Latin America, Asia-Pacific
and Africa, Fresenius Medical Care provides dialysis treatment to 214,648 patients around the globe. FMC is also the world’s
leading provider of dialysis products such as hemodialysis machines, dialyzers
and related disposable products. FMC is listed on the Frankfurt Stock Exchange
(FME, FME3) and the New York Stock Exchange (FMS, FMS/P).
FMC’s worldwide operations are divided into two segments: North America and International.
In order to strengthen its market position in the area of dialysis
services in the Asian Pacific region, FMC acquired Asia Renal Care Ltd. in
2010. This firm is the second largest
dialysis provider in the region after FMC.
For
the year ended 31st December, 2010, the net revenue of the FMC Group amounted
to US$12,053 million, grew by 7.2% as compared with US$11,247 million in
FY 2009; net income amounted to US$979 million, grew by 9.9% as compared with
US$891 million in FY 2009.
The
Group also maintains manufacturing facilities in European and Asian countries
as well as in Latin America.
As
at 31st December, 2010, the Group had 73,452 employees (2009: 67,988).
The
subject is fully supported by the FMC Group.
On the whole,
consider it good for normal business engagements.
REMARKS:
Brief personal profile of the principal director:
Mr. Roberto FUSTE FERNANDEZ, aged 59, is Chief Executive Officer for Asia-Pacific. After completing his studies in Economic Sciences at the University of Valencia, Spain, he founded the company Nephrocontrol S.A. in 1983. After Nephrocontrol was acquired by the Fresenius Group in 1991, he held several senior positions within the Company in the Latin America and Asia-Pacific regions, among others. He was appointed to the Management Board of Fresenius Medical Care in 1999.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.49.71 |
|
UK Pound |
1 |
Rs.78.09 |
|
Euro |
1 |
Rs.68.05 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.